Biogen IDEC

$182.4MPublic contracts won10 public contracts
Data updated Nov 21, 2026Full reportReport a mistake

Facts

as of Nov 21, 2026
Legal name
Biogen IDEC Ltd
Register numbers
CRN 01497267
Official records
Companies House 01497267
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

Biogen holds 75–100% of Biogen IDEC.

Holders
ownership of shares 75 to 100 percent; voting rights 75 to 100 percent; right to appoint and remove directors
75–100%
Legal entities1 in 1 country
operator · GB CRN 01497267
GB
Holders and shares as each register or filing states them.

Products

Products →

Biogen IDEC holds 2 FDA approvals of new drugs and biologics. Biogen IDEC has 1 clinical trials on record, 0 under way.

FDA approvals
Zinbryta
EU authorisation (EMA) · EMEA/H/C/003862 · daclizumab · Multiple Sclerosis
Jul 2016
Plegridy
Biologic (BLA) · BLA125499 · peginterferon beta-1a · injection
Aug 2014
Tysabri
Biologic (BLA) · BLA125104 · natalizumab · single-use
Nov 2004
Biggest buyers10 · $182.4M
NHS England
United Kingdom · 8 public contracts
$181.8M
Regional Business Services Organisation Procurement and Logistics Service
United Kingdom · 1 public contract
$298k
Belfast Health & Social Care Trust
United Kingdom · 1 public contract
$294k
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.

Biogen IDEC in public registers.

Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices